These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 32928644)
1. Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease". Hickman RA; Vonsattel JP; Agin-Liebes J; Marder K; Alcalay RN Parkinsonism Relat Disord; 2020 Oct; 79():131-132. PubMed ID: 32928644 [No Abstract] [Full Text] [Related]
2. Letter to the editor, "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease". Koga S; Dickson DW; Wszolek ZK Parkinsonism Relat Disord; 2020 Oct; 79():130. PubMed ID: 32921567 [No Abstract] [Full Text] [Related]
3. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease. Agin-Liebes J; Cortes E; Vonsattel JP; Marder K; Alcalay RN Parkinsonism Relat Disord; 2020 May; 74():76-77. PubMed ID: 31734038 [No Abstract] [Full Text] [Related]
4. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease. Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388 [No Abstract] [Full Text] [Related]
5. Lack of central and peripheral nervous system synuclein pathology in R1441G Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313 [No Abstract] [Full Text] [Related]
6. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease. Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063 [TBL] [Abstract][Full Text] [Related]
7. Misfolded α-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable α-Synuclein Pathology. Kim A; Martinez-Valbuena I; Keith JL; Kovacs GG; Lang AE Mov Disord; 2024 Jan; 39(1):218-220. PubMed ID: 37986700 [No Abstract] [Full Text] [Related]
8. Pathological Functions of LRRK2 in Parkinson's Disease. Jeong GR; Lee BD Cells; 2020 Nov; 9(12):. PubMed ID: 33266247 [TBL] [Abstract][Full Text] [Related]
9. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease. Daher JP Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286 [TBL] [Abstract][Full Text] [Related]
10. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation. Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998 [TBL] [Abstract][Full Text] [Related]
11. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons. Henderson MX; Peng C; Trojanowski JQ; Lee VMY Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356 [TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid biomarkers and clinical features in leucine-rich repeat kinase 2 (LRRK2) mutation carriers. Vilas D; Shaw LM; Taylor P; Berg D; Brockmann K; Aasly J; Marras C; Pont-Sunyer C; Ríos J; Marek K; Tolosa E Mov Disord; 2016 Jun; 31(6):906-14. PubMed ID: 27041685 [TBL] [Abstract][Full Text] [Related]
13. α-synuclein (SNCA) but not dynamin 3 (DNM3) influences age at onset of leucine-rich repeat kinase 2 (LRRK2) Parkinson's disease in Spain. Fernández-Santiago R; Garrido A; Infante J; González-Aramburu I; Sierra M; Fernández M; Valldeoriola F; Muñoz E; Compta Y; Martí MJ; Ríos J; Tolosa E; Ezquerra M; Mov Disord; 2018 Apr; 33(4):637-641. PubMed ID: 29473656 [TBL] [Abstract][Full Text] [Related]
15. Reduced content of α-synuclein in peripheral blood leukocytes of patients with LRRK2-associated Parkinson's disease. Pchelina SN; Emelyanov AK; Yakimovskii AF; Miller DW; Shabalina IG; Drozdova AS; Schwarzman AL Bull Exp Biol Med; 2011 Apr; 150(6):679-81. PubMed ID: 22235415 [TBL] [Abstract][Full Text] [Related]
16. CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson's disease: a study in LRRK2 mutation carriers. Majbour NK; Aasly JO; Hustad E; Thomas MA; Vaikath NN; Elkum N; van de Berg WDJ; Tokuda T; Mollenhauer B; Berendse HW; El-Agnaf OMA Transl Neurodegener; 2020 May; 9(1):15. PubMed ID: 32375873 [TBL] [Abstract][Full Text] [Related]
17. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers. Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086 [TBL] [Abstract][Full Text] [Related]
18. Mutations in LRRK2 impair NF-κB pathway in iPSC-derived neurons. López de Maturana R; Lang V; Zubiarrain A; Sousa A; Vázquez N; Gorostidi A; Águila J; López de Munain A; Rodríguez M; Sánchez-Pernaute R J Neuroinflammation; 2016 Nov; 13(1):295. PubMed ID: 27863501 [TBL] [Abstract][Full Text] [Related]